(Q44041440)

29 November 2017

title

Tacrolimus enhances irritation in a 5-day human irritancy in vivo model (English)

1 reference

29 November 2017

Fuchs M

1

1 reference

29 November 2017

Schliemann-Willers S

series ordinal

2

1 reference

29 November 2017

Heinemann C

series ordinal

3

1 reference

29 November 2017

Elsner P

series ordinal

4

1 reference

29 November 2017

publication date

1 May 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

46

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

290-294

1 reference

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Topical tacrolimus in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Inhibition of contact allergy reactions by topical FK506.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

The mechanism of action of cyclosporin A and FK506

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Erosive mucosal lichen planus: response to topical treatment with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

The soap chamber test. A new method for assessing the irritancy of soaps

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Tacrolimus: the drug for the turn of the millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Irradiation of human skin by short wavelength ultraviolet radiation (100--290 nm) (u.v.C): increased concentrations of arachidonic acid and prostaglandines E2 and F2alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Topical steroid therapy of atopic skin diseases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Skin irritant reactivity following experimental cumulative irritant contact dermatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). Influence of the application time point

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0536.2002.460508.X

7 January 2021

10.1034/J.1600-0536.2002.460508.X

Identifiers

DOI

1 reference

29 November 2017

1 reference